Ceftezole, a cephem antibiotic, is an α-glucosidase inhibitor with in vivo anti-diabetic activity

International Journal of Molecular Medicine

Volumn 20, Issue 3, 2007, Pages 379-383

  Lee, Dong Sun ^a,d   Lee, Jin Man ^b   Kim, Sung Uk ^c   Chang, Kyu Tae ^c   Lee, Sang Han ^a  

^a Kyungpook National University   (South Korea)

^b Kyongbuk College of Science   (South Korea)

^c Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

glucosidase; Anti diabetic; Ceftezole; In vitro; In vivo; Inhibitor;

Indexed keywords

ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; ANTIINFECTIVE AGENT; CEFMENOXIME; CEFTERAM; DRUG DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PRIMER DNA;

ANIMAL; ARTICLE; BLOOD; C57BL MOUSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL DIABETES MELLITUS; FEMALE; GENE EXPRESSION; GENETICS; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; METABOLISM; MOUSE; NUCLEOTIDE SEQUENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALPHA-GLUCOSIDASES; ANIMALS; ANTI-BACTERIAL AGENTS; BASE SEQUENCE; BLOOD GLUCOSE; CEFMENOXIME; DIABETES MELLITUS, EXPERIMENTAL; DNA PRIMERS; DRUG EVALUATION, PRECLINICAL; FEMALE; GENE EXPRESSION; GLYCOGEN SYNTHASE KINASE 3; HYPOGLYCEMIC AGENTS; MICE; MICE, INBRED C57BL; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 35148887227     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.20.3.379     Document Type: Article

References (25)

1. Lebovitz HE and Banerji MA: Treatment of insulin resistance in diabetes mellitus. Eur J Pharmacol 490: 135-146, 2004.
2. Singleton JR, Smith AG, Russell JW and Feldman EL: Microvascular complications of impaired glucose tolerance. Diabetes 52: 2867-2873, 2003.
3. Leslie RD and Pozzilli P: Type I diabetes masquerading as type II diabetes. Possible implications for prevention and treatment. Diabetes Care 17: 1214-1219, 1994.
4. Newell AM: Genetics for targeting disease prevention: diabetes. Prim Care 31: 743-766, 2004.
5. Rich SS and Concannon P: Challenges and strategies for investigating the genetic complexity of common human diseases. Diabetes 51: S288-S294, 2002.
6. Herold KC, Baumann E, Vezys V and Buckingham F: Expression and immune response to islet antigens following treatment with low doses of streptozotocin in H-2d mice. J Autoimmun 10: 17-25, 1997.
7. Harris F, Chatfield L, Singh J and Phoenix DA: Role of calpains in diabetes mellitus: a mini review. Mol Cell Biochem 261: 161-167, 2004.
8. Lee DS and Lee S-H: Genistein, a soy isoflavone, is a potent alpha-glucosidase inhibitor. FEBS Lett 501: 84-86, 2001.
9. Segel IH: Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme System. Wiley, New York, pp100-202, 1975.
10. Tam J, Rosenberg L and Maysinger D: INGAP peptide improves nerve function and enhances regeneration in streptozotocin-induced diabetic C57BL/6 mice. FASEB J 18: 1767-1769, 2004.
11. Kawa JM, Taylor CG and Przybylski R: Buckwheat concentrate reduces serum glucose in streptozotocin-diabetic rats. J Agric Food Chem 51: 7287-7291, 2003.
12. Winchester B and Fleet GW: Amino-sugar glycosidase inhibitors: versatile tools for glycobiologists. Glycobiology 2: 199-210, 1992.
13. Bischoff H: Pharmacology of alpha-glucosidase inhibition. Eur J Clin Invest Suppl 3: 3-10, 1994.
14. Hirsh AJ, Yao SY, Young JD and Cheeseman CI: Inhibition of glucose absorption in the rat jejunum: a novel action of alpha- D-glucosidase inhibitors. Gastroenterology 113: 205-211, 1997.
15. Caspary WF: Sucrose malabsorption in man after ingestion of alpha-glucoside hydrolase inhibitor. Lancet 1: 1231-1233, 1978.
16. Gruters RA, Neefjes JJ, Tersmette M, de Goede RE, Tulp A, Huisman HG, Miedema F and Ploegh HL: Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature 330: 74-77, 1987.
17. Dennis JW, Laferte S, Waghorne C, Breitman ML and Kerbel RS: Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. Science 236: 582-585, 1987.
18. Fonseca V: Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Curr Med Res Opin 19: 635-641, 2003.
19. Wehmeier UF and Piepersberg W: Biotechnology and molecular biology of the alpha-glucosidase inhibitor acarbose. Appl Microbiol Biotechnol 63: 613-625, 2004.
20. Li WL, Zheng HC, Bukuru J and De Kimpe N: Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol 92: 1-21, 2004.
21. Anjaneyulu M and Chopra K: Fluoxetine attenuates thermal hyperalgesia through 5-HT1/2 receptors in streptozotocin-induced diabetic mice. Eur J Pharmacol 497: 285-292, 2004.
22. Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH and Pederson RA: Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52: 741-750, 2003.
23. Noto T, Nehashi T, Endo H, Saito M and Matsubara S: Ceftezole, a new cephalosporin C derivative. I. In vitro and in vivo antimicrobial activity. J Antibiot 29: 1058-1070, 1976.
24. Nishida M, Murakawa T, Kamimura T, Okada N, Sakamoto H, Fukada S, Nakamoto S, Yokota Y and Miki K: In vitro and in vivo evaluation of ceftezole, a new cephalosporin derivative. Antimicrob Agents Chemother 10: 1-13, 1976.
25. De Sarro A, Ammendola D, Zappala M, Grasso S and De Sarro GB: Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrob Agents Chemother 39: 232-237, 1995.